Physician profile
Robert B Ecker
NPI 1811950074
$8,121.23
in general payments reported to CMS, 2019-2025
31 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,811 · 2020: $700 · 2021: $1,214 · 2022: $1,436 · 2023: $860 · 2024: $1,008 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,960.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,626.72 | 2019-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $1,263.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $837.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $651.09 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $650.53 | 2019-2025 | Cabtreo, Jublia |
| Leo Pharma INC. | $472.90 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $397.27 | 2019-2022 | |
| Genzyme Corporation | $377.38 | 2019-2025 | |
| Amgen INC. | $367.03 | 2020-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $264.54 | 2019-2022 | |
| Lilly USA, LLC | $193.10 | 2019-2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $139.85 | 2020-2025 | Nemluvio |
| Ucb, INC. | $126.47 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $85.04 | 2023-2025 | Sotyktu |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $82.24 | 2021-2022 | |
| Genentech USA, INC. | $66.33 | 2019 | |
| Merz North America, INC. | $58.96 | 2025 | |
| Biofrontera INC. | $56.92 | 2019-2025 | Ameluz |
| Verrica Pharmaceuticals INC. | $46.18 | 2024 | Ycanth |
| Incyte Corporation | $42.64 | 2021-2022 | |
| Celgene Corporation | $35.81 | 2019 | |
| Mission Pharmacal Company | $30.72 | 2019-2020 | |
| Almirall LLC | $30.11 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $26.22 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.90 | 2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $18.73 | 2020 | |
| Arcutis Biotherapeutics, INC. | $18.37 | 2023 | |
| Kyowa Kirin, INC. | $15.94 | 2020 | |
| Epi Health, LLC | $10.46 | 2019 | |
| Organon LLC | $6.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.